Stryker stock faces lower 2026 outlook after Q3 earnings miss
Published on 11/09/2026 at 16:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSOutlook cut weighs on earnings picture
- Stryker reported 7.7 percent third-quarter sales growth, but management said performance fell short of expectations.
- Adjusted operating margin expanded to 26.2 percent despite weaker reported earnings.
- Full-year organic sales and adjusted earnings guidance now stands below the previous ranges.
Stryker lowered its full-year 2026 outlook after third-quarter performance fell short of management expectations on October 29. The medical-technology company reported stronger sales and adjusted profitability, but a goodwill impairment weighed on reported earnings.
Growth remained uneven
According to the Stryker release published by GlobeNewswire, third-quarter sales rose 7.7 percent to USD 6.52 billion. MedSurg and Neurotechnology sales increased 9.2 percent to USD 3.7 billion, while Orthopaedics grew 5.7 percent to USD 2.9 billion.
Reported net earnings fell 12.3 percent to USD 753 million, and diluted earnings per share declined 11.7 percent to USD 1.96. The quarter included a USD 293 million goodwill impairment. On an adjusted basis, net earnings rose 10.1 percent to USD 1.4 billion, adjusted earnings per share increased 10.3 percent to USD 3.52, and adjusted operating margin widened 60 basis points to 26.2 percent.
Guidance reset raises execution pressure
Stryker now expects 2026 organic sales growth of 6.5 to 7.0 percent, down from 8.3 to 9.3 percent previously. Adjusted diluted earnings per share are forecast at USD 14.80 to USD 14.90, compared with the former range of USD 14.95 to USD 15.10.
The company said its underlying fundamentals remained strong and expects solid fourth-quarter performance and momentum entering 2027. Investors will focus on procedure volumes, execution in Orthopaedics and the ability to preserve margin expansion as the lower sales outlook works through the business.
What has changed since the last report
Stryker stock traded at 291.10 euros on Lang & Schwarz at 16:39 CET on Monday, November 9, 2026. That was 1.24 percent below the 294.75 euros recorded in the latest relevant report on the same day at 14:24 CET; this separate comparison does not represent a Xetra day move.
Stryker Corporation stock facts
- Company: Stryker Corporation
- ISIN: US8636671013
- Ticker: SYK
- Home exchange: NYSE
- Lang & Schwarz quote: 291.10 euros on November 9, 2026, at 16:39 CET
- Change since the latest relevant report: 1.24 percent below 294.75 euros on November 9, 2026, at 14:24 CET
- Sector: Healthcare
- Industry: Medical devices
The S&P 500 provides the broader market backdrop for the US-listed medical-technology company.
